

TÜRK
ÜROONKOLOJİ
DERNEĞİ - 1999




ASCO GU

2026

Güncelleme

19-20 Haziran 2026

Samsun



ASCO GU 2026 Güncelleme

19 Haziran Cuma

13:15-13:30	Açılış Dr. Ender Özden Dr. Şaban Sarıkaya, Dr. Murat Danacı
13:30-15:30	1. Oturum Non-Muscle-Invasive Bladder Cancer Management in Transition: Integrating Emerging Evidence Into Practice Oturum Başkanları: Dr. Kamil Çam, Dr. Y. Kamil Yakupoğlu
13:30-13:50	Optimizing Surgical Management of Non-Muscle-Invasive Bladder Cancer Dr. Saadettin Eskiçorapçı
13:50-14:10	Optimizing Radiation Therapy for Non-Muscle-Invasive Bladder Cancer Dr. Nilgün Özbek Okumuş
	Karşıtlık
14:10-14:25	For: Bacillus Calmette-Guérin Plus Immune Checkpoint Inhibition for High-Risk Non-Muscle-Invasive Bladder Cancer Dr. Evren Süer
14:25-14:40	Against: Bacillus Calmette-Guérin Plus Immune Checkpoint Inhibition for High-Risk Non-Muscle-Invasive Bladder Cancer Dr. Deniz Bolat



19 Haziran Cuma

14:40-15:20	Seçilmiş Bildiriler
14:40-15:00	Dr. Murat Gülşen
	Abstract 630: Neoadjuvant and Adjuvant Enfortumab Vedotin Plus Pembrolizumab for Participants with Muscle-Invasive Bladder Cancer Who Are Eligible for Cisplatin: Randomized, Open-Label, Phase 3 KEYNOTE-B15 Study.
	Abstract 638: Pathological Outcomes and Disease-Free Survival in KEYNOTE-905: Neoadjuvant and Adjuvant Enfortumab Vedotin Plus Pembrolizumab in Participants with Muscle-Invasive Bladder Cancer Who Are Cisplatin-Ineligible.
	Abstract 737: Phase 2 Trial of Pembrolizumab with Response-Guided Bladder-Sparing in Patients with Muscle-Invasive Bladder Cancer (HCRN GU 20-444).
	Abstract 629: SWOG S1602: A Phase III Randomized Trial to Evaluate The Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy For BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer (NCT #03091660).

ASCO GU 2026

Güncelleme

19 Haziran Cuma

	Abstract 637: Induction Ipilimumab Plus Nivolumab Followed By Consolidating Chemoradiotherapy As Bladder-Sparing Treatment in Stage II/III Urothelial Carcinoma of The Bladder: The Phase 2 INDIBLADE Trial.
15:00-15:20	Dr. Emre Yekedüz
	Abstract 632: Circulating Tumor DNA (ctDNA) To Guide Response-Adapted Bladder Preservation in Muscle Invasive Bladder Cancer: Integrated Analysis of The RETAIN Trials.
	Abstract 633: Circulating Tumor ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer: Exploratory Analysis of ctDNA Dynamics in The IMvigor011 Trial.
	Abstract 634: Keymaker-U04 Substudy 04B: First-Line Enfortumab Vedotin Plus Pembrolizumab-Based Immune Checkpoint Inhibitor Combinations for Advanced Urothelial Cancer.
	Abstract 636: Urinary Tumor DNA and Circulating Tumor DNA in Patients with Muscle-Invasive Bladder Cancer Who Received Perioperative Durvalumab in NIAGARA.
15:20-15:30	Soru-Cevap



19 Haziran Cuma

15:30-16:00	Kahve Arası ☕
16:00-17:15	2. Oturum Multidisciplinary Tumor Board: Innovative Approaches To Bladder Preservation Moderatör: Dr. Sümer Baltacı
	Dr. Pervin Hürmüz, Dr. Yasemin Kemal, Dr. Güven Aslan, Dr. Murat Danacı

ASCO GU 2026

Güncelleme

20 Haziran Cumartesi

09:00-10:15	1. Oturum Innovations in Kidney Cancer in 2026: Diagnostics, Novel Targets, and Trial Design Oturum Başkanları: Dr. Sinan Sözen, Dr. Cenk Yücel Bilen
09:00-09:15	Imaging For Renal Cell Carcinoma: Current State of The Art Dr. Cemil Aydın
09:15-09:30	Emerging Tools in Imaging in Renal Cell Carcinoma Dr. Mehmet Necmettin Mercimek
09:30-09:50	Novel Targets in Kidney Cancer Dr. Emre Yekedüz
	Seçilmiş Bildiriler
09:50-10:05	Dr. İsmail Önder Yılmaz
	Abstract 420: Patient-Reported Outcomes In Resected Renal Cell Carcinoma: Active Monitoring vs. Durvalumab and Tremelimumab in The RAMPART Trial.
	Abstract 421: Ultra-Sensitive Whole-Genome Sequencing-Based Molecular Residual Disease Detection in Resectable Renal Cell Carcinoma: Preliminary Results From The MONSTAR-SCREEN-3 Study.
	Abstract 537: Circulating KIM-1 and ctDNA As Prognostic Markers in Oligometastatic Clear Cell Renal Cell Carcinoma: The K-COMPASS Model.



20 Haziran Cumartesi

10:05-10:15	Soru-Cevap
10:15-10:45	Kahve Arası ☕
10:45-12:15	2. Oturum Multidisciplinary Tumor Board: Challenges and Opportunities in Treating Patients with Advanced Kidney Cancer Moderatör: Dr. Volkan İzol
	Dr. Oktay Üçer, Dr. Yüksel Ürün, Dr. Selim Nural, Dr. H. Cem Önal
12:15-13:00	Öğle Yemeği 🍴
13:00-14:45	3. Oturum Balancing Cure and Quality: Navigating Functional Outcomes in Localized Prostate Cancer Oturum Başkanları: Dr. Levent Türkeri, Dr. Nalan Alan Selçuk
13:00-13:15	Minimizing Harm: Surgical Approaches to Preserve Continence and Sexual Function Dr. Bahadır Şahin
13:15-13:30	Precision Matters: How Radiation Choices Shape Quality of Life Dr. H. Cem Önal

ASCO GU 2026 Güncelleme

20 Haziran Cumartesi

	Treatment Selection, Response Assessment, and Monitoring Across The Spectrum of Advanced Prostate Cancer
13:30-13:50	Making Sense Of Many Options: Metastatic Hormone-Sensitive Prostate Cancer Treatment Selection Dr. Mustafa Erman
13:50-14:10	Evaluation and Definition of Response and Progression From Trials To Clinical Practice Dr. Yüksel Ürün
14:10-14:30	New Treatment Options for Patients with Castrate-Resistant Prostate Cancer Dr. İbrahim Karadağ
14:30-14:45	Soru-Cevap
14:45-16:00	4. Oturum Multidisciplinary Tumor Board: From Imaging to Molecular Insights—Tailoring Therapy Intensity in Localized/Locally Advanced Prostate Cancer Moderatör: Dr. İlker Tinay
	Dr. Pervin Hürmüz, Dr. İlkay Çamlıdağ, Dr. Mustafa Erman, Dr. Serdar Çelik
16:00-16:10	Kahve Arası ☕



20 Haziran Cumartesi

16:10-16:45	Seçilmiş Bildiriler
16:10-16:30	Dr. Serhat Çetin
	Abstract 307: Androgen Deprivation Therapy and Radiotherapy With or Without Cabazitaxel In Very-High Risk Localized Prostate Cancer: First Results of The PEACE-2 Randomized Phase III Trial.
	Abstract 309: Genomic Alterations and Pathologic Responses to Neoadjuvant Androgen Receptor Pathway Inhibitor Doublets +/- Docetaxel In SP-2 of The Genomic Umbrella Neoadjuvant Study (GUNS).
	Abstract 305: Hormone Therapy Use and Duration With Postoperative Radiotherapy for Recurrent Prostate Cancer: An Individual Patient Data Meta-Analysis.
	Abstract 16: Overall Survival From The Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAaway).

ASCO GU 2026 Güncelleme

20 Haziran Cumartesi

16:30-16:45	Dr. Nazım Coşkun
	Abstract 15: Final Overall Survival Results From The EORTC 1333/ PEACE-3 Trial: Enzalutamide With or Without Radium-223 in Metastatic Castration-Resistant Prostate Cancer.
	Abstract 18: Health-Related Quality of Life, Pain, and Symptomatic Skeletal Events in The Phase 3 PSMAddition Study of [¹⁷⁷ Lu] Lu-PSMA-617 (¹⁷⁷ Lu-PSMA-617) Combined with ADT and ARPI in Patients With PSMA-positive mHSPC.
	Abstract 19: First-in-Human Assessment of Actinium-225-Prostate-Specific Membrane Antigen (²²⁵ Ac-PSMA)-Trillium™ (BAY 3563254) in mCRPC: Dose-Escalation Results of The Phase 1 PAnTHA Study.
	Kapanış

TÜRK
ÜROONKOLOJİ
DERNEĞİ - 1999

